Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Mid-Morning Market Update: Markets Mixed; Dow Drops 50 Points

U.S. stocks traded mixed this morning, with the Dow Jones dropping around 50 points on Tuesday.

Benzinga

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

The Guardian - UK

Pfizer Fails To Boost Its 2022 Outlook, But Shares Rise

Pfizer stock fell Tuesday after its 2022 outlook missed overly bullish sales estimates. The company also cut its earnings view.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Posts Street Beating Q1 Earnings, Revises FY22 Profit Outlook

Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50. The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion. Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues. Eliquis…

Benzinga

Dow Jones Falls Ahead Of Fed Meeting; 7 Key Earnings Movers

The Dow Jones Industrial Average fell Tuesday ahead of the Fed's two-day meeting. Mosaic and Pfizer were among seven key earnings movers.

Investors Business Daily

Pfizer: Q1 Earnings Insights

Pfizer (NYSE:PFE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:45 AM. Here's what investors need to know about the announcement. Earnings Pfizer beat estimated earnings by 8.0%, reporting an EPS of $1.62 versus an estimate of $1.5.

Benzinga

North East deals of the week: contracts, acquisitions and investments

Businesses involved in deals across the region include RSA Insurance, Roman Ltd, Tait Walker and ReViral

Birmingham Post

Read news from The Economist, FT, and more,
with one subscription

3 High-Quality Stocks to Buy During This Market Selloff

The near-term market outlook remains cloudy. While the S&P 500 is about 3% above its late-February lows, the Nasdaq and Russell 2000 have already undercut these levels. Below are 3 such stocks that investors should consider buying during this market correction: Anthem (ANTM), Pfizer (PFE), and Builders FirstSource (BLDR).

StockNews.com

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 16 strange trades.

Benzinga

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Benzinga

Option Trade Profits If Pfizer Stock's Earning Reaction Isn't Crazy

This iron condor trade has the potential to return 32% if the stock price stabilizes and implied volatility drops.

Investors Business Daily

Lanarkshire senior nurse urges parents of young children to consider COVID-19 vaccine

The Pfizer vaccine was approved for youngsters in December 2021.

Daily Record

She wanted to vaccinate their kids against COVID. He didn't. A judge had to decide

A divorced Pennsylvania couple could not agree on whether to vaccinate their children — and ended up in court. Since the vaccine was approved for kids, cases like these have skyrocketed in the state.

WEKU

Pfizer says its COVID-19 treatment Paxlovid fails to prevent infection of household members

A trial of 3,000 adults finds that the COVID-19 oral antiviral treatment, Paxlovid, is not effective at preventing cross-infection in people living with someone with the virus.

ABC News

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

This Is What Whales Are Betting On Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Benzinga

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)…

Investors Business Daily

Novavax Surges As Its Covid Shot Approaches The FDA Finish Line

The Food and Drug Administration said Friday its panel of experts will discuss Novavax's Covid vaccine in June, leading NVAX stock to surge.

The Independent UK

FDA sets June meetings on COVID vaccines for youngest kids

The Food and Drug Administration has set tentative dates in June to publicly review COVID-19 vaccines for the youngest American children

Get all your
news in one place.

100’s of premium titles.
One news app.

The National (Scotland)

Scottish campaigners protest at Pfizer office as 'vaccine equity' motion voted down

CAMPAIGNERS from Global Justice Now Scotland have stated they are “outraged” as shareholders at pharmaceutical multinationals Pfizer and Moderna…

Salon

White House: Paxlovid shortage is over

As VP Harris takes Paxlovid after her COVID-19 diagnosis, the White House is making the drug easier to access

Benzinga

FDA Gives Green Signal To Pfizer's Duchenne Gene Therapy Trial

After the FDA lifted its hold on a late-stage study, Pfizer Inc (NYSE:PFE) said it would open the first U.S. trial sites for its experimental gene therapy for a muscle-wasting disorder. The FDA had put Pfizer's Investigational New Drug (IND) application for fordadistrogene movaparvovec on hold, and Pfizer has addressed the agency's requests related…

The Independent UK

Moderna seeks FDA approval of Covid vaccine for children aged six months to five years old

The request arrives one month after the drug company said its two-dose jabs provided immune protection in youngest children

Evening Standard

Covid vaccine: Moderna seeks US approval for jab for kids under 6

Trials showed the jab was 37 per cent effective for two and five-year-olds and 51 per cent for children between six months and the age of two

Tribune News Service

Moderna applies for US clearance of COVID shot for young kids

Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.

The Independent UK

Moderna seeks to be 1st with COVID shots for littlest kids

Moderna is asking U.S. regulators to open its COVID-19 vaccine to the nation's youngest children

1 … 52 53 54 55

People

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.